Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449APTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known **Application Number** 10/040,010 Filing Date January 4, 2002 First Named Inventor Thomas M. Mills Group Art Unit 1614 **Examiner Name** Unknown Attorney Docket Number M0351-267875 EV 032 110 529 US **Express Mail Certificate**

| Sub | stitute f | or form 1449. | APTO | | 00 | | (|
|------------------------|-------------------------|--------------------------|------------------------|--------------------------------------|---|---|---|
| SUPPLEMENTAL | | | | | Application Number | 10/040,010 | |
| INFORMATION DISCLOSURE | | | | | Filing Date | January 4, 2002 | |
| | STATEMENT DV ADDI ICANT | | | | First Named Inventor | 1 g g | |
| 7 | STATEMENT BY APPLICANT | | | ICANI | Group Art Unit | 1614 | |
| As | | · /ueo se | many sheets as necessa | and) | Examiner Name | Unknown | |
| A . | | (036 03 | many sneets as necessa | · y) | Attorney Docket Number | M0351-267875 | |
| Sh | eet | 1 of | 2 | | Express Mail Certificate | EV 032 110 529 US | |
| 37 | | | | | - | | 60 |
| 8 | | | | | | | 8 - |
| RE | | | | U.S. P. | ATENT DOCUMENTS | | 1600 1800 |
| | | | U.S. Patent Do | cument | | | 4 |
| xaminer nitials* | | Cite No. ¹ | Number | Kind Code ² (if known) | Name of Patentee or Applicant of Cited Document | Date of Publication Cited Document MM-DD-YYYY | Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear |
| | | | 2002/0013304 | A1 | Leland F. Wilson et al. | 01-31-02 | |
| ~ | V- | | 2002/0013304 | - 101 | Leiand 1 . VVIISON et al. | 01-31-02 | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | - | _ |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | · · · · · · · · · · · · · · · · · · · |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

| * | | | | FOREIG | N PAT | ENT DOCUMEN | ITS | | | |
|-----------------------|--------------|---|-------------------|---|-------|---|-----|---|--|----------|
| | | 1 | Foreign Patent Do | cument | | | | | | |
| Examiner Initials* | Cite No.1 | Office ³ Number ⁴ | | Number ⁴ Kind Code ² (if known) | | Name of Patentee or Applicant of Cited Document | | f Publication of d Document I-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | Т° |
| 390 | | EP | 0 956 865 | A1 | | Yoshitomi Pharmaceutic al Industries, Ltd. | | 11-17-99 | | 1 |
| | | wo | 99/21562 | A1 | | Vivus, Inc. | | 05-06-99 | | 1 |
| | X . | wo | 96/14748 | A1 | | Nirec, Inc. | | 05-23-96 | | √ |
| | | | | | | | | | | |
| | <u> </u> | | | | | | | | | |
| | | | | | | | | | | + |

| Examiner Signature | 5050 | Date Considered | l | //5 | 10 | ጕ | |
|-----------------------|---|-------------------------------|-------|-----------|-----------|-----|------------|
| *EXAMINER: In | itial if reference considered, whether or not citation is in conformance with MPEP 609. | Draw line through citation if | not/i | n conform | ation and | not | considered |
| Include copy of t | his form with next communication to applicant. | | ı | | , | | |

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Examiner

Signature

Under the Paperwork Reduction Act of 1995, no persons are required to respond

| Approved for use through 10/31/2002, OMB 0551-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE to a collection of information unless it contains a valid OMB control number | |
|---|--|
| to a consection of into matter transcript contains a vein come contain mainten | |

| Subs | litute for form 1449APTO |
|------|---|
| | INFORMATION DISCLOSURE STATEMENT BY APPLICANT |
| E) | (use as many sheets as necessary) |

Complete if Known **Application Number Filing Date** First Named Inv ntor Group Art Unit **Examiner Name** Attorney Docket Number

2 of

| 1915 | | | |
|----------|--------------|---|---------|
| | | OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS | |
| Examiner | Cite No.1 | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T² |
| | | | |
| 3917 | | MEDICAL COLLEGE OF GEORGIA, News Releases, On Line, "New Pathway for Treating Erectile Dysfunction Identified by MCG Researchers", News Releases on line December 29, 2000 (XP002200836) http://www.mcg.edu/news | 1 |
| | | MILLS, T. M., Vasoconstriction and the Erectile Response", <i>Issir</i> Newsbulletin on line Vol. 5, see 20-21, January 2001 (XP-002200837) http://www.issir.org | 1 |
| | | MILLS, T. M., "Vasoconstriction and the Erectile Response", Issir Newsbulletin on line 1 of 3 (IP-002200838) http://www.issir.org | ~ |
| | | MILLS, T. M. et al., "Nitric Oxide Inhibits RhoA/Rho-Kinase signaling to cause penile erection", European Journal of Pharmacology, 439 (1-3) 173-4 (3-29-02) | |
| SAC | Y | PCT Notification of Transmittal of the International Search Report or the Declaration for PCT/US02/00006 filed on 04-01-02, mailing date 08-29-02, pages 1 and 2 | ~ |
| | | | _ |
| | - | | |
| | | | _ |
| | | • | _ |
| | | | \perp |
| | | | |
| | | | |
| | | | П |
| | | | Ī |
| | 1 | | ╁ |
| | | | † |
| | | | + |
| | | <u> </u> | + |
| | | | ╁ |
| | | | +- |
| | - | | + |
| | | | 1 |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in-conformation and not considered. Include copy of this form with next communication to applicant.

Date Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. M0351-267875 WINLIB01:968574.1



¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.



Approved for use through 10/31/20es DMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMStantrol register

Complete if Known

"action Number 10/040,010

Ianuary 4, 2002 INFORMA Group Art Unit Unassigned **Examiner Name** Unassigned **Attorney Docket Number** M0351-267875 Sheet 1 of 4 Express Mail Certificate EV 032 197 074 US

| | | U.S | S. Patent Docu | ment | | | | | | | |
|-----------------------|--------------|---------------------|-------------------------------------|--------------------------------------|-------|---|---------------|--|-------|--|-------------|
| Examiner Initials* | crte No.' | Number | | Kind Code ² (if known) | N | ame of Patentee or App of Cited Document | licant | Date of Pub Cited Door MM-DD-Y | ument | Pages, Columns, I Where Releva Passages or Rele Figures Appea | nt evant |
| - | 1 | 4,127,11 | 8 | | Laton | e, Alvaro | | 11-28-78 | | | |
| | 2 | 4,801,58 | 7 | | Voss, | Gene et al. | | 01-31-89 | | • | |
| | 3 | 4,968,67 | 9 | i i | Bodo | Junge, Wuppertal | et al. | 11-06-90 | | | |
| | 4 | 5,059,60 | 3 | | Rubin | , David | | 10-22-91 | | | |
| | 5 | 5,242,39 | 1 | | Place | , V. A. et al. | | 09-07-93 | | | |
| | 6 | 5,256,65 | 2 | | El-Ra | shidy, Ragab | | 10-26-93 | | | |
| | 7 | 5,888,53 | 4 | | El-Ra | shidy, Ragab et a | l. | 03-30-99 | | | |
| | 8 | 5,945,11 | 7 | | El-Ra | shidy, Ragab et a | l. | 08-31-99 | | | |
| | 9 | 5,981,56 | 3 | | Lowre | ey, Fred | | 11-09-99 | | | |
| | 10 | 6,007,82 | 4 | | | ett, M. J. et al. | | 12-28-99 | | | |
| | 11 | 6,051,59 | | | Lowre | ey, Fred | | 04-18-00 | | | |
| | 12 | 6,087,36 | 2 | | El-Ra | shidy, Ragab | | 07-11-00 | | | |
| | 13 | 6,093,18 | 1 | | | , V. A. et al. | | 07-25-00 | | | |
| | 14 | 6,100,27 | | | Camp | bell, S. F. | | 08-08-00 | | | |
| i i | 15 | 6,100,28 | 6 | | Lowre | ey, Fred | | 08-08-00 | | | |
| | 16 | 6,124,33 | 7 | | Lowre | ey, Fred | | 09-26-00 | | | |
| | 17 | 6,166,06 | i1 | | Lowre | ey, Fred | | 12-26-00 | | | |
| | 18 | 6,239,11 | 7 B1 | | Chris | t, G. J. et al. | | 05-29-01 | | | |
| 5/4 | 19 | 6,266,56 | 0 B1 | | Zhan | g, L. et al. | | 07-24-01 | | | |
| | | | | FOREIGI | N PAT | ENT DOCUMEN | ITS | | | | |
| | | Fore | eign Patent Doc | ument | | | | | | | |
| Examiner Initials* | Cite No.1 | Office ³ | Number ⁴ | Kind Code ² (if known) | | me of Patentee or nt of Cited Document | Cited | Publication of Document -DD-YYYY | Pass | s, Columns, Lines, /here Relevant sages or Relevant igures Appear | T |
| 590 | 200 | | 03246A abstract ranslation) | | | Yoshitomi Pharmaceu- tical Industries Ltd. | | 05-31-00 | - | | - |
| | 21 | EP 0 | 633023A1 | | | Eli Lilly & Co. | | 01-11-95 | | | 7 |
| | 22 | | 048254 abstract ranslation) | | | Eli Lilly & Co. | | 02-21-95 | | | 1 |
| | 23 | WO 9 | 98/06433 abstract ranslation) | | | Yoshitomi Pharmaceu- tical Industries Ltd. | | 02-19-98 | · | | ~ |
| 100 | 24 | | 0/33845 abstract ranslation) | | | Yoshitomi Pharmaceu- tical Industries Ltd. | | 06-15-00 | | | ~ |
| Examiner Signature | | < | | 57 | | | Date Consi | dorod | U | 15/62 | L |

Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

2 of

Sheet

| | | OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS | |
|-----------------------|--------------|---|----------|
| Examiner Initials* | Cite No.' | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T² |
| 59 | 25 | AMANO, M., et al., Phosphorylation and Activation of Myosin by Rho- associated Kinase (Rho-kinase), J. Biol. Chem., 271, 20246-20249, 1996 | 1 |
| | 26 | ANDERSSON, K.E., Pharmacology of Penile Erection, <i>Pharmacol. Rev.</i> , 53 , 417-450, September 2001 | 1 |
| | 27 | APENSTROM, P., Effectors for the RHO GTPases, Curr. Opin. Cell. Biol., 11, 95-102, 1999 | 1 |
| | 28 | BERMAN, J.R., et al., Anatomy and Physiology of Female Sexual Function and Dysfunction, <i>Eur. Urology</i> 38 , 20-29, 2000 | ~ |
| | 29 | BIVALACQUA, T.J., et al., Adenoviral gene transfer of endothelial nitric oxide synthase (eNOS) to the penis improves age-related erectile dysfunction in the rat, <i>Int. J. Impotence Res.</i> , 12 , S8-S17, September 2000 | ~ |
| | 30 | BURNETT, A.L., Role of Nitric Oxide in the Physiology of Erection, <i>Biol. Reprod.</i> , 52 , 485-489, 1995 | ~ |
| | 31 | CHAMPION, H.C., et al., Gene transfer of endothelial nitric oxide synthase to the penis augments erectile responses in the aged rat, <i>Proc. Natl. Acad. Sci., USA</i> , 96 , 11648-11652, 1999 | ~ |
| | 32 | CHITALEY, K., et al., Antagonism of Rho-kinase stimulates rate penile erection via nitric oxide-independent pathway, <i>Nature Med.</i> , 7 , 119-122, January 2001 | ~ |
| | 33 | CHITALEY, K., et al., RhoA/Rho-kinase: a novel player in the regulation of penile erection, <i>Int'l J. of Impotence Research</i> , 13 , 67-72, April 2001 | 1 |
| | 34 | CHITALEY, K., et al., Decreased penile erection in DOCA-salt and stroke prone-spontaneously hypertensive rats, <i>Int'l J. of Impotence Research</i> , 13 , Suppl 5, S16-S20, December 2001 | ~ |
| | 35 | CHRIST, G.J., et al., The application of gene therapy to the treatment of erectile dysfunction, <i>Int. J. Impotence Res.</i> , 10 , 111-112, 1998 | 1 |
| | 36 | CHRIST, G. J., et al., Intracorporal injection of <i>hSlo</i> cDNA in rats produces physiologically relevant alterations in penile function, <i>Am. J. Physiol.</i> , 275 , H600-608, 1998 | 1 |
| | 37 | DAI, Y., et al., Receptor-specific influence of endothelin-1 in the erectile response of the rat, <i>Am. J. Physiol. Regulatory Integrative Compl. Physiol.</i> , 279 , R25-R30, July 2000 | ~ |
| | 38 | DiSALVO, J., et al., Vanadate-Induced Contraction of Smooth Muscle and Enhanced Protein Tyrosine Phosphorylation, <i>Arch. Biochem. Biophys.</i> , 304 , 386-391, 1993 | ~ |
| | 39 | DUCKERS, H.J., et al., Heme oxygenase-1 protects against vascular constriction and proliferation, <i>Nature Med.</i> , 7 , 693-698, June 2001 | ~ |
| | 40 | FENG, et al., Rho-associated Kinase of Chicken Gizzard Smooth Muscle, J. Biol Chem., 274, 3744-3752, 1999 | ' |
| | 41 | GARBAN, H., et al., Cloning of Rat and Human Inducible Penile Nitric Oxide Synthase. Application for Gene Therapy of Erectile Dysfunction, <i>Biol. Reprod.</i> , 56 , 954-963, 1997 | ~ |
| 5/4 | 42 | ISHIZAKI, T., et al., Pharmacological Properties of Y-27632, a Specific | 1 |

32 1/15/04

Substitute for form 1449APTD

Sheet

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Under the Paperwork Rediction Fact of 1995

JUH 2 7 2002

INFORMATION DISCLOSERE STATEMENT APPROPRIATE

(use as many sheets as necessary)

13 10 4

| Complete if Known | | | | | | |
|------------------------|---------------------|------|--|--|--|--|
| Application Number | 10/040,010 | Ch y | | | | |
| Filing Date | January 4, 2002 | Co | | | | |
| First Named Inventor | Mills, T. M. et al. | Wx 0 | | | | |
| Group Art Unit | Unassigned | Eq. | | | | |
| Examiner Name | Unassigned | "// | | | | |
| Attorney Docket Number | M0351-267875 | 000 | | | | |
| | • | | | | | |

| 99 | Inhibitor of Rho-associated Kinases, <i>Mol. Pharmacol.</i> , 57 , 976-983, May 2000 | |
|--------|---|----------|
| 43 | and Response to Prior Treatment J. Urology 162, 722-725, 1999 | V |
| 44 | Associated Kinase (Rho-Kinase), Science, 273, 245-248, 1997 | ✓ |
| 45 | KUREISHI, Y., et al., Rho-associated Kinase Directly Induces Smooth Muscle Contraction through Myosin Light Chain Phosphorylation, <i>J. Biol. Chem.</i> , 272 , 12257-12260, 1997 | ✓ |
| 46 | LOWRY, O.H., et al., Protein Measurement with the Folin Phenol Reagent, J. Biol. Chem., 193, 265-275, 1951 | ✓ |
| 47 | MILLS, T., et al., Androgen Maintenance of Erectile Function in the Rat Penis, <i>Biol. Reprod.</i> , 46 , 342-348, 1992 | √ |
| 48 | Hemodynamics of Penile Erection in the Rat, <i>Biol. Reprod.</i> , 51 , 234-238, 1994 | ✓ |
| 49 | Rat, Steroids, 64, 605-609, 1999 | ✓ |
| 50 | during Erection in the Rat, Biol. Reprod., 59, 1413-1418, 1998 | ✓ |
| 51 | Response, Int'l J. of Impotence Research, Suppl 3, Abstract A1, September 2000 | ✓ |
| 52 | MILLS, T., et al., Inhibition of the Rho Kinase Pathway Leads to Penile Erection, 9 th World Meeting on Impotence Research, Perth Australia, Abstract P6, Nov. 26-30, 2000 | √ |
| 53 | MILLS, T., et al., Vasoconstrictors in erectile physiology, <i>Int'l J. of Impotence Research</i> , 13 , Suppl 5, S29-S34, December 2001 | √ |
| 54 | penile circulation, J. Appl. Physiol., 91, 1269-1273, September 2001 | ✓ |
| 55 | TheScientificWorld, 1, 184-185, May 2001 | √ |
| 56 | on the Rat Erectile Response, J. Urology, 158, 942-947, 1997 | ✓ |
| 57 | NO and other relaxing factor derived from nerves, Am J. Physiol., 274, H1075-H1081, 1998 | √ |
| 58 | smooth muscle contraction, Acta Physiol. Scand., 164, 449-456, 1998 | ✓ |
| 59 | REES, R. W., et al., Y-27632, an inhibitor of Rho-kinase, antagonizes noradrenergic contraction in the rabbit and human penile corpus cavernosum, <i>British J. of Pharmacology</i> , 133 , 455, June 2001 | ✓ |
| 60 | REES, R. W., et al., Human and rabbit cavernosal smooth muscle cells express Rho-kinase, <i>Int'l J. of Impotenance Research</i> , 14 , 1-7, February 2002 | √ |
| 500 61 | REILLY, C.M., et al., Androgens Modulate the α-Adrenergic Responsiveness of Vascular Smooth Muscle in the Corpus Cavernosum, J. | ✓ |

PTO/SB/OBA (08-00)
Approved for use through 10/31/2002. OMBAS 10031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
5, no persons are required to respond to a collection of information unless it contains a yalid OMB control (10) ber

Substitute for form 1449APTO

Sheet

JUH 2 7 2002

INFORMATION DISCLOSE E STATEMENT BY APPLICANT

(use as many sheets as necessary)

4 08 4

| Con | plete if Known | Ca |
|------------------------|---------------------|----|
| Application Number | 10/040,010 | W. |
| Filing Date | January 4, 2002 | 6 |
| First Named Inventor | Mills, T. M. et al. | 77 |
| Group Art Unit | Unassigned | |
| Examiner Name | Unassigned | |
| Attorney Docket Number | M0351-267875 | |
| | - | |

| | | <u> </u> | | | | | |
|---------|--------------|--|--|----------|--|--|--|
| 1/4 | H) | Ž | of Andrology, 1, 26-31, 1997 | | | | |
| 7 | 1 | | | | | | |
| | | 62 | REILLY, C.M., et al., Androgenic Regulation of NO Availability in Rat Penile | ✓ | | | |
| | | | Erection, J. Andrology, 18, 110-115, 1997 | | | | |
| | | 63 | REILLY, C.M., et al., Androgenic Maintenance of the Rat Erectile Response | ✓ | | | |
| | ł | | Via a Non-Nitric-Oxide-Dependent Pathway, J. Andrology, 18, 588-594, | | | | |
| | l | | 1997 | | | | |
| | | 64 | RIDLEY, A., RHO: theme and variations, Curr. Biol., 6, 1256-1264, 1996 | 1 | | | |
| | 1 | 65 | SAHAI, E., et al., RhoA effector mutants reveal distinct effector pathways | √ | | | |
| | Į. | | for cytoskeletal reorganization, SRF activation and transformation, EMBO | | | | |
| | | | J., 17 , 1350-1361, 1998 | | | | |
| | | 66 | SAUZEAU, V., et al., Cyclic GMP-dependent Protein Kinase Signaling | √ | | | |
| | | | Pathway Inhibits RhoA-induced Ca ²⁺ Sensitization of Contraction in | | | | |
| | ì | | Vascular Smooth Muscle, <i>J. Biol. Chem.</i> , 275 , 21722-21729, July 2000 | | | | |
| | | 67 | SAWADA, N., et al., cGMP-Dependent Protein Kinase Phosphorylates and | ✓ | | | |
| | | 0, | Inactivates RhoA, <i>Biochem. Biophys. Res. Comm.</i> , 280 , 798-805, January | | | | |
| | 1 | | 26, 2001 | | | | |
| | 1 | 68 | SCHOTT, E., et al., Expression of a recominant preproendothelin-1 gene in | 1 | | | |
| | | | arteries stimulates vascular contractility, , <i>Am. J. Physiol.</i> , 272 , H2385- | | | | |
| | | | H2393, 1997 | | | | |
| | | 69 SOMLYO, A.P., et al., From pharmacomechanical coupling to G-proteins | | | | | |
| | İ | and myosin phosphatase, <i>Acta Physiol. Scand.</i> , 164 , 437-448, 1998 | | | | | |
| | | 70 | SOMLYO, et al., Signal transduction by G-proteins, Rho-kinase and protein | ✓ | | | |
| | | ,,,, | phosphatase to smooth muscle and non-muscle myosin II, <i>J. Physiol.</i> , 522 , | | | | |
| | 1 | | 177-185, January 2000 | | | | |
| | | 71 | TRAISH, A., et al., Role of alpha adrenergic receptors in erectile function, | ✓ | | | |
| | | | Int. J. Impot. Res., 12, Suppl. 1, S48-63, March 2000 | | | | |
| | 1 | 72 | UEHATA, M., et al., Calcium sensitization of smooth muscle mediated by a | ✓ | | | |
| | 1 | - | Rho-associated protein kinase in hypertension, <i>Nature</i> , 389 , 990-994, 1997 | | | | |
| |] | | , | | | | |
| | 1 | 73 | VIRAG R., Indications and Early Results of Sildenafil (VIAGRA) in Erectile | 1 | | | |
| | l. | | Dysfunction, <i>Urology</i> 54 , 1073-77, 1999 | | | | |
| | 1 | 74 | WEBER, et al., Enhanced Relaxation to the Rho-Kinase Inhibitor Y-27632 | 1 | | | |
| | | | in Mesenteric Arteries from Mineralocorticoid Hypertensive Rats, | | | | |
| | | | Pharmacology, 63, 129-133, October 2001 | | | | |
| | \top | 75 | WINGARD, C. J., et al., Recovery of Penile Erection by Inhibition of Rho- | 1 | | | |
| | | | Kinase in a Castrate Rat Model of Erectile Dysfunction, Int'l J. of Impotence | | | | |
| | | | Research, 13, Suppl 5, Abstract 1, December 2001 | | | | |
| | +- | 76 | WINGARD, C. J., et al., Erection and NO override the vasoconstrictive | ✓ | | | |
| 123 | | 1 | effect of α-adrenergic stimulation in the rat penile vasculature, <i>Int'l J. of</i> | | | | |
| | 7 | | Impotence Research, 13, 212-220, August 2001 | | | | |
| Examin | ner | | Date 1660 V. | | | | |
| Signatu | 1 | | Considered (//S/70 4 | | | | |
| | | | | _ | | | |

Signature EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformation and not

^{*}EXAMINER: Initial if reference considered, whether or for citation is in conformance with MPEP 609. Draw line through citation in not in conformation and not conformation of the include copy of this form with next communication to applicant.

*Unique citation designation number. Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

M0351-267875 WINLIB01:932491.1

ype a plus sign (+) inside this box

PTO/SB/OBA (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449APTO

Sheet 1 of 1

3rd SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known Application Number 10/040,010 Filing Date January 4, 2002 First Named Inventor Thomas M. Mills Group Art Unit 1617 **Examiner Name** Bahar, Mojdeh Attorney Docket M0351-267875 (011-00) Number **Express Mail Certificate** EV 315 188 141 US

| OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS | | | | | | | |
|---|--------------|---|---------|--|--|--|--|
| Examiner Initials* | Cite No.1 | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T | | | | |
| | | | | | | | |
| H | 1 | LAUFS, U. et al., Post-transcriptional Regulation of Endothelial Nitric Oxide Synthase mRNA Stability by Rho GTPase, <i>J. Bio. Chem.</i> , Vol. 273, No. 37, pp. 24266-24271, 1998. | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | - | | | | | | |
| | | | | | | | |
| | | | 1 | | | | |
| | | | | | | | |
| | | | \perp | | | | |
| | | | + | | | | |

| | , , | / |
|---|------------------------|--------|
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation | if not in conformation | |
| and dead in the state of the constitution of the constitution is in containing the wint MFEP 605. Didw line through dialion is | a not in comornation | and no |
| considered. Include copy of this form with next communication to applicant. | / | |

Date

Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

M0351-267875 WINLIB01: 1032460.1

Examiner

Signature

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/O8A (08-00)
Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449APTO 2nd SUPPLEMENTAL INFORMATION DISCLOSURE

2 of 2

STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complet if Known **Application Number** 10/040,010 Filing Date January 4, 2002 First Named Inventor Thomas M. Mills Group Art Unit 1617 Examiner Name Hui, San Ming R. M0351-267875 (011-00) Attorney Docket Number EV 127 539 264 US **Express Mail Certificate**

| ARK | | OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS | |
|-------------------|--------------|---|----------------|
| Examiner nitials* | Cite No.¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | Τ ['] |
| ACI | 2 | DAVIS, S. P. et al., Specificity and mechanism of action of some commonly used protein kinase inhibitors, <i>Biochem. J.</i> , 351 , 95-105, 2000 | ~ |
| | 3 | HIROSE, M. et al., Molecular dissection of the RHO-associated protein kinase (p160ROCK)-regulated neurite remodeling in neuroblastoma N1E-115 cells, <i>J. Cell Biol.</i> , 141 , 1625-1636, 1998 | ~ |
| | 4 | MAEKAWA, M. et al., Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase, <i>Science</i> , 285 , 895-898, 1999 | ~ |
| 39G) | 5 | NARUMIYA, S. et al., Use and properties of ROCK-specific inhibitor Y-27632, Methods Enzymol, 325:273-84, 2000 | ~ |
| | | | |
| | | 4 50 | t |
| | | | + |
| | | | lacksquare |
| | | الله بم الله | F |
| | | | F |
| | | 33 | ļ |
| | | | + |
| | | | + |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.

Date

Considered


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Petent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.


M0351-267875 WINLIB01:1002297.1

Examiner

Signature

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.





Examiner

Substitute for form 1449APTO

Please type a plus sign (+) inside this box

2nd SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of 2

| Complete if Known | | | | | | |
|--------------------------|-----------------------|--|--|--|--|--|
| Application Number | 10/040,010 | | | | | |
| Filing Date | January 4, 2002 | | | | | |
| First Named Inventor | Thomas M. Mills | | | | | |
| Group Art Unit | 1617 | | | | | |
| Examiner Name | Hui, San Ming R. | | | | | |
| Attorney Docket Number | M0351-267875 (011-00) | | | | | |
| Express Mail Certificate | EV 127 539 264 US | | | | | |

| | | | U.S. P | ATENT DOCUMENTS | | | |
|--------------------|--------------------------|-------------|--------------------------------------|---|---|---|--|
| | | U.S. Patent | Document | | | | |
| Examiner Initials* | Cite No. ¹ | Number | Kind Code ² (if known) | Name of Patentee or Applicant of Cited Document | Date of Publication Cited Document MM-DD-YYYY | Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear | |
| | 1 | 4,997,834 | | Tomio Muro et al. | 03-05-91 | | |
| | | | | | | | |
| | | | | 111111111111111111111111111111111111111 | | APR 2 3 | |
| | | | | | | 8 2003 IR 1600/ | |
| | | | | | | 12000 | |
| | | - | | | | <u> </u> | |

| | | | | FOREIG | N PAT | ENT DOCUMEN | ITS | | | |
|-----------------------|--------------------------|---|-------------------------|--------------------------------------|--|-------------|--|---|--|----|
| Examiner Initials* | | For | Foreign Patent Document | | | | | | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | |
| | Cite No. ¹ | Office ³ Number ⁴ | | Kind Code ² (if known) | Name of Patentee or Applicant of Cited Document | | Date of Publication of Cited Document MM-DD-YYYY | | | Т° |
| | | | | | | | | | | |
| | | | | | | | | _ | | + |
| | | + | | | | | | | | + |
| | | + | | | | | | | | +- |
| | + | | | | | | | | | 1 |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | 11/7 | | | | | | _ |
| | | | | | | | | | | |

Considered Signature EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformation and not Include copy of this form with next communication to applicant.

Date

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

